1-ethynyl-1-trimethylsiloxycyclopentane | 62785-89-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-ethynyl-1-trimethylsiloxycyclopentane
• 英文别名: (1-trimethylsiloxycyclopentyl)ethyne；(1-ethynylcyclopentyloxy)trimethylsilane；2-(1-trimethylsiloxycyclopentyl)ethyne；[(1-Ethynylcyclopentyl)oxy](trimethyl)silane；(1-ethynylcyclopentyl)oxy-trimethylsilane
• CAS: 62785-89-1
• 化学式: C₁₀H₁₈OSi
• 分子量: 182.338
• InChiKey: HFRUZPLOOJGQHV-UHFFFAOYSA-N

物化性质

• 沸点：
  176.7±19.0 °C(Predicted)
• 密度：
  0.90±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.78
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-ethynyl-1-trimethylsiloxycyclopentane 在 乙基溴化镁 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 1-乙炔基环戊醇
  参考文献：
  名称：

  摘要：

  Effects of structural factors in silyl ethers derived from terminal acetylenic alcohols on 1,4-O-->C-sp migration of the silyl group in the Iotsitch reagent were studied. The effect of steric factor at the carbon atom neighboring to the reaction center was found to be stronger than that at the silicon atom in the migrating group.

  DOI：

  10.1023/a:1025529428307
• 作为产物：
  描述：

  1-乙炔基环戊醇 、 六甲基二硅氮烷 在 EDNA 作用下， 反应 3.5h， 以95%的产率得到1-ethynyl-1-trimethylsiloxycyclopentane
  参考文献：
  名称：

  摘要：

  Effects of structural factors in silyl ethers derived from terminal acetylenic alcohols on 1,4-O-->C-sp migration of the silyl group in the Iotsitch reagent were studied. The effect of steric factor at the carbon atom neighboring to the reaction center was found to be stronger than that at the silicon atom in the migrating group.

  DOI：

  10.1023/a:1025529428307

文献信息

• Manganese‐Catalyzed Carbonylative Annulations for Redox‐Neutral Late‐Stage Diversification
  作者：Yu‐Feng Liang、Ralf Steinbock、Annika Münch、Dietmar Stalke、Lutz Ackermann

  DOI：10.1002/anie.201801111

  日期：2018.5.4

  inexpensive, nontoxic manganese catalyst enabled unprecedented redox‐neutral carbonylative annulations under ambient pressure. The manganese catalyst outperformed all other typically used base and precious‐metal catalysts. The outstanding versatility of the manganese catalysis manifold was reflected by ample substrate scope, setting the stage for effective late‐stage manipulations under racemization‐free

  廉价，无毒的锰催化剂可在环境压力下实现前所未有的氧化还原中性羰基环化反应。锰催化剂的性能优于所有其他常用的碱金属和贵金属催化剂。充足的底物范围反映了锰催化歧管出色的多功能性，为在无消旋条件下对许多市售药物和天然产物（包括生物碱，氨基酸，类固醇和碳水化合物）进行有效的后期操作奠定了基础。
• [EN] 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES À SUBSTITUTION EN 1,2
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2009158393A1

  公开（公告）日：2009-12-30

  1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

  描述了一种抑制磷酸二酯酶10的1,2-二取代杂环化合物。还描述了这些化合物在治疗哺乳动物，包括人类的中枢神经系统（CNS）疾病和可能影响CNS功能的其他疾病中的过程、药物组成、药物制剂和药物用途。可以治疗的疾病包括神经病、神经退行性疾病和精神疾病，包括但不限于与认知缺陷或精神分裂症症状相关的疾病。
• 1,2-disubstituted heterocyclic compounds
  申请人：EnVivo Pharmaceuticals, Inc.

  公开号：US08071595B2

  公开（公告）日：2011-12-06

  1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

  本文描述了抑制磷酸二酯酶10的1,2-二取代杂环化合物。同时还描述了这些化合物的制备方法、制药组合物、制药制剂以及在哺乳动物（包括人类）治疗中枢神经系统（CNS）疾病和其他可能影响CNS功能的疾病中的制药用途。这些疾病包括但不限于与认知缺陷或精神分裂症状有关的神经学、神经退行性和精神障碍。
• 1,2-Disubstituted Heterocyclic Compounds
  申请人：Ripka Amy

  公开号：US20100137317A1

  公开（公告）日：2010-06-03

  1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

  本文描述了抑制磷酸二酯酶10的1,2-二取代杂环化合物。同时还描述了这些化合物的制备过程、制药组合物、制药制剂以及在治疗哺乳动物（包括人类）的中枢神经系统（CNS）疾病和其他可能影响CNS功能的疾病中的制药用途。可治疗的疾病包括神经、神经退行性和精神障碍，包括但不限于与认知缺陷或精神分裂症状相关的疾病。
• 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS
  申请人：EnVivo Pharmaceuticals, Inc.

  公开号：US20140011808A1

  公开（公告）日：2014-01-09

  1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

  本文描述了一种抑制磷酸二酯酶10的1,2-二取代杂环化合物。同时还描述了这些化合物的制备过程、制药组合物、制药制剂以及在治疗哺乳动物（包括人类）的中枢神经系统（CNS）疾病和其他可能影响CNS功能的疾病中的制药用途。这些疾病包括神经系统、神经退行性和精神障碍，包括但不限于与认知缺陷或精神分裂症状相关的疾病。